CANF Can-Fite BioPharma Ltd: Earnings per share for the last 12 months

Can-Fite BioPharma, Ltd. (CANF) - corporate logo

Risks for Can-Fite BioPharma (CANF) are linked to the narrow market for A3AR agonists in oncology. The year-over-year change in EPS (TTM) illustrates this volatility, where the current parameter equals 82.70. Growth potential is driven by molecule patents that guarantee pricing power, although revenue is currently limited to Asian licenses at the late-stage clinical trial phase.

Can-Fite BioPharma, Ltd. (CANF) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/13/2026

CANF (Can-Fite BioPharma, Ltd.): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price canfite.com|CANF - Price Target Chart
- company stock capitalization data:
Market Capitalization Can-Fite BioPharma Ltd|CANF - Enterprise Value
- book capitalization indicators:
Accounting Value per Share Can-Fite BioPharma|CANF - Company Book Value|Market-to-Book Ratio canfite.com|CANF - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Can-Fite BioPharma|CANF - Long-Term Debt to Equity|Current Liabilities to Capital Can-Fite|CANF - Company Aggregate Debts|Debt to Net Assets Can-Fite BioPharma Ltd|CANF - Company Long-Term Liabilities|Short-Term Debt Can-Fite BioPharma|Intermediate Coverage Ratio canfite.com
- earnings and market multiples details:
CANF - Net Income|Future Net Profit Can-Fite BioPharma|CANF - P/E Multiple|Future Price to Earnings Multiple Can-Fite BioPharma Ltd|CANF - PEG Multiple|Company Value to EBITDA Can-Fite BioPharma Ltd|CANF - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Can-Fite BioPharma|CANF - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth canfite.com|CANF - Earnings per share growth in current year|Net earnings per share change forecast for next year Can-Fite BioPharma
- revenue and sales details:
CANF - Company Sales|Company Expected Sales Volume canfite.com|CANF - P/S Multiple|Forward Price-to-Revenue Multiple Can-Fite BioPharma Ltd
Fundamental company valuation:CANF canfite.com
Flagship merchandise of Can-Fite BioPharma Ltd.

This metric reflects the rolling year net income per share, allowing for an assessment of business capitalization efficiency through historical EPS YoY growth over the last 12 months. A positive trend in this metric confirms the ability of Can-Fite BioPharma (CANF) to monetize unique patents in oncology and hepatology, creating a sustainable barrier against pricing pressure from generics.

Direct competitors

Net earnings per one share for the last twelve months incyte.com|HUTCHMED (HCM) - Earnings per share for the last twelve months|Earnings per share for the last 12 months NUVB|DAWN (Day One Bio) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Monopar Corp (MNPR)|Earnings per share for the last twelve months Inhibrx Biosciences (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc. FENC|Heron - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Coherus Biosciences|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla Corp BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology Holdings)|CTXR (citiuspharma.com) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (biolinerx.com)|Aprea - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (Kazia Therapeutics)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana (NCNA)|Earnings per share for the last twelve months Chimerix, Inc.|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Inc (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Corp) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months